Citations

Showing 10 of 108104 citations.

Cross-leg free flap for limb salvage in the setting of radiation
Bishop, Sarah N. , Martinez‐Jorge, Jorys, Adabi, Kian , Manrique, Oscar J.

Mayo Clinic

BMJ Case Reports | August 10, 2018 | Volume: 2018 | Issue: No issue available | Pages: bcr-2018-224563

10.1136/bcr-2018-224563 | PMID 30097544 Get It

Limb salvage in an irradiated patient with limited recipient vessels leaves few options for reconstruction. Cross-leg free flaps have been used to reconstruct defects that would otherwise lead to amputation in patients with no ipsilateral recipient vessels. We present the first documented case of a cross-leg free flap for limb salvage in a radiated bed after infection and tumour resection.
Three VCP Mutations in Patients with Frontotemporal Dementia
Wong, Tsz Hang, Pottier, Cyril , Hondius, David , Meeter, Lieke , Rooij, Jeroen van , Melhem, Shami, bank, The Netherlands Brain, Minkelen, Rick van , Duijn, Cornelia M. van , Rademakers, Rosa , van Duijn, Cornelia M , Pottier, Cyril , bank, The Netherlands Brain, Rozemüller, Annemieke J.M. , Seelaar, Harro , Swieten, John C. van

Mayo Clinic

Journal of Alzheimer’s Disease | August 10, 2018 | Volume: 65 | Issue: 4 | Pages: 1139-1146

10.3233/jad-180301 | PMID 30103325 Get It

Valosin-containing protein ( VCP) is involved in multiple cellular activities. Mutations in VCP lead to heterogeneous clinical presentations including inclusion body myopathy with Paget’s disease of the bone, frontotemporal dementia and amyotrophic lateral sclerosis, even in patients carrying the same mutation. We screened a cohort of 48 patients with familial frontotemporal dementia (FTD) negative for MAPT, GRN, and C9orf72 mutations for other known FTD genes by using whole exome sequencing. In addition, we carried out targeted sequencing of a cohort of 37 patients with frontotemporal lobar degeneration with Transactive response DNA-binding protein 43 (TDP-43) subtype from the Netherlands Brain bank. Two novel (p.Thr262Ser and p.Arg159Ser) and one reported (p.Met158Val) VCP mutations in three patients with a clinical diagnosis of FTD were identified, and were absence in population-match controls. All three patients presented with behavioral changes, with additional semantic deficits in one. No signs of Paget or muscle disease were observed. Pathological examination of the patient with VCP p.Arg159Ser mutation showed numerous TDP-43 immunoreactive (IR) neuronal intranuclear inclusions (NII) and dystrophic neurites (DN), while a lower number of NII and DN were observed in the patient with the VCP p.Thr262Ser mutation. Pathological findings of both patients were consistent with FTLD-TDP subtype D. Furthermore, only rare VCP-IR NII was observed in both cases. Our study expands the clinical heterogeneity of VCP mutations carriers, and indicates that other additional factors, such as genetic modifiers, may determine the clinical phenotype.
Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma Network
Rauert‐Wunderlich, Hilka , Mottok, Anja , Rimsza, Lisa M. , Ott, German , Klapper, Wolfram , Unterhalt, Michael, Hartmann, Sylvia , Thorns, Christoph, Rymkiewicz, Grzegorz , Dreyling, Martin , Hoster, Eva , Rosenwald, Andreas , Rimsza, Lisa M , Ott, German , Klapper, Wolfram , Holte, Harald , Scott, David W. , Kluin‐Nelemans, Hanneke C. , Hermine, Olivier , Holte, Harald , Hoster, Eva

Mayo Clinic

British Journal of Haematology | August 10, 2018 | Volume: 184 | Issue: 4 | Pages: 616-624

10.1111/bjh.15519 | PMID 30095158 Get It

SummaryMantle cell lymphoma (MCL) is still considered incurable and the course of the disease is highly variable. Established risk factors include the Mantle Cell Lymphoma International Prognostic Index (MIPI) and the quantification of the proliferation rate of the tumour cells, e.g. by Ki‐67 immunohistochemistry. In this study, we aimed to validate the prognostic value of the gene expression‐based MCL35 proliferation assay in patient cohorts from randomized trials of the European Mantle Cell Lymphoma Network. Using this assay, we analysed the gene expression proliferation signature in routine diagnostic lymph node specimens from MCL Younger and MCL Elderly trial patients, and the calculated MCL35 score was used to assign MCL patients to low (61%), standard (27%) or high (12%) risk groups with significantly different outcomes. We confirm here in our prospective clinical trial cohort of MCL patients, that the MCL35 assay is strongly prognostic, providing additional information to the Ki‐67 index and the MIPI. Thus, this robust assay may assist in making treatment decisions or in devising risk‐adapted prospective clinical trials in the future.
Editorial: biologic therapies for primary sclerosing cholangitis—more disappointment than promise? Authors’ reply
Tse, Chung Sang , Loftus, Edward V. , Raffals, Laura E. , Gossard, Andrea A., Lightner, Amy L. , Tse, C S , Lightner, A L , Loftus, Edward V

Mayo Clinic

Alimentary Pharmacology & Therapeutics | August 10, 2018 | Volume: 48 | Issue: 5 | Pages: 578-579

10.1111/apt.14907 | PMID 30156321 Get It

Linked ContentThis article is linked to Tse et al and Ma and Kotze paper. To view these articles visit https://doi.org/10.1111/apt.14829 and https://doi.org/10.1111/apt.14858.
Physiological and pathological high frequency oscillations in focal epilepsy
Cimbálník, Jan , Brinkmann, Benjamin H. , Křemen, Václav , Jurák, Pavel , Berry, Brent , Stead, Matt, Brinkmann, Benjamin, Brinkmann, Benjamin H , Kremen, Vaclav , Gompel, Jamie J. Van , Worrell, Gregory A.

Mayo Clinic

Annals of Clinical and Translational Neurology | August 10, 2018 | Volume: 5 | Issue: 9 | Pages: 1062-1076

10.1002/acn3.618 | PMID 30250863 Get It

Abstract Objective This study investigates high‐frequency oscillations ( HFO s; 65–600 Hz) as a biomarker of epileptogenic brain and explores three barriers to their clinical translation: (1) Distinguishing pathological HFO s (path HFO ) from physiological HFO s (phys HFO ). (2) Classifying tissue under individual electrodes as epileptogenic (3) Reproducing results across laboratories. Methods We recorded HFO s using intracranial EEG ( iEEG ) in 90 patients with focal epilepsy and 11 patients without epilepsy. In nine patients with epilepsy putative phys HFO s were induced by cognitive or motor tasks. HFO s were identified using validated detectors. A support vector machine ( SVM ) using HFO features was developed to classify tissue under individual electrodes as normal or epileptogenic. Results There was significant overlap in the amplitude, frequency, and duration distributions for spontaneous phys HFO , task induced phys HFO , and path HFO , but the amplitudes of the path HFO were higher ( P < 0.0001). High gamma path HFO had the strongest association with seizure onset zone ( SOZ ), and were elevated on SOZ electrodes in 70% of epilepsy patients ( P < 0.0001). Failure to resect tissue generating high gamma path HFO was associated with poor outcomes ( P < 0.0001). A SVM classified individual electrodes as epileptogenic with 63.9% sensitivity and 73.7% specificity using SOZ as the target. Interpretation A broader range of interictal path HFO (65–600 Hz) than previously recognized are biomarkers of epileptogenic brain, and are associated with SOZ and surgical outcome. Classification of HFO s into physiological or pathological remains challenging. Classification of tissue under individual electrodes was demonstrated to be feasible. The open source data and algorithms provide a resource for future studies.
Can Ultrasound Identify Paradoxical Vocal Fold Movement? A Pilot Study
Orbelo, Diana M. , Ekbom, Dale C. , Finnoff, Jonathan T. , Orbelo, Diana

Mayo Clinic

Clinical Journal of Sport Medicine | August 10, 2018 | Volume: 30 | Issue: 5 | Pages: e120-e123

10.1097/jsm.0000000000000641 | PMID 30095506 Get It

Objective: Vocal cord dysfunction (VCD) is characterized by paradoxical vocal fold movement (PVFM) during inspiration. The aim of this study was to determine whether ultrasound could accurately differentiate between normal and PVFM during respirations in a resting state. Design: Prospective, single-subject design. Setting: Academic medical center. Patients: A speech-language pathologist who was able to volitionally alternate between normal and PVFM when breathing at rest was recruited to participate in the study. Interventions: The subject was instructed to randomly alternate between normal and PVFM 20 times (10 times each). A single investigator imaged the vocal folds using ultrasound and reported when the subject alternated between the 2 respiratory states. Main Outcome Measures: The subject recorded when they changed between the 2 respiratory states, whether the investigator identified with the change occurred, and if the correct respiratory state was identified. Results: The investigator recognized when the subject changed respiratory states and correctly identified the new respiratory state 100% of the time. Conclusions: The findings of the current study were promising and suggest that ultrasound may have utility in the diagnosis of VCD. However, because of the preliminary nature of these results, further research is required before recommending its clinical implementation.
Characterization of Passive Wireless Electrocardiogram Acquisition in Adult Zebrafish
Gruber, Silviu, Wilson, Konnor, Yang, Jingchun , Cao, Hung , Le, Tai , Huerta, Miguel, Xu, Xiaolei

Mayo Clinic

2018 IEEE International Microwave Biomedical Conference (IMBioC) | August 9, 2018 | Volume: No volume available | Issue: No issue available | Pages: 115-117

10.1109/imbioc.2018.8428899 Get It

Mycobacterium avium Complex and Bronchiectasis. There’s Something Happening Here..
Griffith, David E. , Aksamit, Timothy R.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | August 9, 2018 | Volume: 198 | Issue: 10 | Pages: 1252-1253

10.1164/rccm.201807-1243ed | PMID 30092144 Get It

Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children’s Oncology Group
Hawkins, Douglas S. , Chi, Yueh-Yun, Anderson, James R. , Tian, Jing , Arndt, Carola A.S., Bomgaars, Lisa , Donaldson, Sarah S. , Hayes‐Jordan, Andrea , Mascarenhas, Leo , McCarville, Mary Beth, McCune, Jeannine S. , McCowage, Geoffrey , Million, Lynn , Parham, David M. , Rodeberg, David A. , Rudzinski, Erin R. , Shnorhavorian, Margarett , Spunt, Sheri L. , Skapek, Stephen X. , Teot, Lisa A., Yock, Torunn I. , Meyer, William H. , McCowage, Geoff, Morris, Carol D. , Hawkins, Douglas S , Spunt, Sheri L , Donaldson, Sarah S , Mascarenhas, Leo , McCarville, Mary Beth, Wolden, Suzanne L.

Mayo Clinic

Journal of Clinical Oncology | August 9, 2018 | Volume: 36 | Issue: 27 | Pages: 2770-2777

10.1200/jco.2018.77.9694 | PMID 30091945 Get It

Purpose Intermediate-risk rhabdomyosarcoma (RMS) includes patients with either nonmetastatic, unresected embryonal RMS (ERMS) with an unfavorable primary site or nonmetastatic alveolar RMS (ARMS). The primary aim of this study was to improve the outcome of patients with intermediate-risk RMS by substituting vincristine and irinotecan (VI) for half of vincristine, dactinomycin, and cyclophosphamide (VAC) courses. All patients received a lower dose of cyclophosphamide and earlier radiation therapy than in previous trials. Patients and Methods Patients were randomly assigned at study entry to either VAC (cumulative cyclophosphamide dose, 16.8 g/m 2 ) or VAC/VI (cumulative cyclophosphamide dose, 8.4 g/m 2 ) for 42 weeks of therapy. Radiation therapy started at week 4, with individualized local control plans permitted for patients younger than 24 months. The primary study end point was event-free survival (EFS). The study design had an 80% power (5% one-sided α-level) to detect an improved long-term EFS from 65% (with VAC) to 76% (with VAC/VI). Results A total of 448 eligible patients were enrolled in the study. At a median follow-up of 4.8 years, the 4-year EFS was 63% with VAC and 59% with VAC/VI ( P = .51), and 4-year overall survival was 73% for VAC and 72% for VAC/VI ( P = .80). Within the ARMS and ERMS subgroups, no difference in outcome by treatment arm was found. Severe hematologic toxicity was less common with VAC/VI therapy. Conclusion The addition of VI to VAC did not improve EFS or OS for patients with intermediate-risk RMS. VAC/VI had less hematologic toxicity and a lower cumulative cyclophosphamide dose, making VAC/VI an alternative standard therapy for intermediate-risk RMS.